OXLUMO™ is the first and only FDA-approved treatment for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels
OXLUMO has been shown to reduce urinary oxalate in infants, children, and adults with primary hyperoxaluria type 1 (PH1).1 By decreasing the production of oxalate in the liver, OXLUMO targets the underlying cause of the disease.1
Treatment with OXLUMO significantly reduced urinary oxalate (UOx) in patients with PH11
Treatment with OXLUMO resulted in a 53% reduction in 24-hour UOx excretion from baseline to month 6 for OXLUMO compared to placebo in a double-blind clinical trial of 39 patients aged >6 years with eGFR ≥30 mL/min/1.73 m2.*,1
Least squares mean reduction averaged over months 3 through 6, corrected for BSA (OXLUMO, 65%; placebo, 12%); 95% CI: 45%, 62%; P<0.0001 vs placebo.
The dosing regimen for OXLUMO led to a rapid reduction in 24-hr UOx within 2 weeks, which was sustained through 6 months1
After receiving 3 monthly starting doses, patients ≥10 kg received OXLUMO once per quarter.1
There’s more to learn about OXLUMO
When you sign up, we will keep you informed with updates and resources.
Here for patients treated with OXLUMO
Alnylam Assist® can help your patients get access to OXLUMO and will provide support for patients throughout their treatment journey.
References: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc. 2. Milliner DS, Harris PC, Cogal AG, et al. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated November 30, 2017. Accessed November 16, 2020. 3. Hoppe B, Beck BB, Milliner DS. Kidney Int. 2009;75(12):1264-1271. 4. Hopp K, Cogal AG, Bergstralh EJ, et al; for Rare Kidney Stone Consortium. J Am Soc Nephrol. 2015;26(10):2559-2570. 5. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736.
Reference: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc.